-

Thermo Fisher Scientific Launches Scalable Diomni Enterprise Software for Molecular Diagnostics Labs and Test Developers

Time to qPCR-based diagnostic results reduced by over two hours and improved lab collaboration with automated quality control and interpretation

CARLSBAD, Calif.--(BUSINESS WIRE)--To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific today has introduced Diomni Enterprise Software, helping streamline routine diagnostics testing for standardization and faster time-to-results. By connecting workflow steps within one interface, Diomni Enterprise can increase a lab’s ability to dynamically respond to today’s rapidly changing testing environment. The solution can be used by a variety of labs performing routine quantitative polymerase chain reaction (qPCR) diagnostic tests and by developers to increase the speed of innovation for emerging testing solutions.

Molecular diagnostics clinical labs and kit manufacturers often suffer from antiquated systems that can be hard to scale for increased throughput or expanding test menu. Further, manual and inefficient steps may make it difficult to track samples and maintain compliance, which is critical for a molecular diagnostics laboratory. For assay developers, transitions between development stages and a lack of process standardization can slow time-to-market and jeopardize regulatory compliance.

Addressing these challenges, Diomni Enterprise seamlessly connects the individual steps of the workflow in one unified platform to improve productivity of qPCR workflows. Diomni Enterprise empowers labs to operate at their highest potential by automating the interface with existing laboratory information systems (LIS) for enhanced efficiency and traceability.

“During the pandemic, we worked to quickly launch a digital solution that would allow clinical labs to continue operations, taking into account the dramatic changes in the PCR testing landscape,” said Fernando Beils, vice president, general manager of qPCR instruments, Thermo Fisher Scientific. “What followed was the earliest stages of the Diomni solution, delivering a digital platform that supports testing workflows with the flexibility required to accommodate rapidly evolving needs. We have continued to build on this platform and are excited to deliver a more robust and scalable tool for labs and assay developers across testing environments.”

Uniting labs with instruments, assays, and LIS on one system can increase traceability to track samples and reagents throughout the sample journey and allows multiple individual users to access assay templates and results at the same time. Diomni Enterprise supports a variety of different testing workflows including compatibility with research-use only and in vitro diagnostic assays and instruments.

“The new Diomni Software makes it easy to work collaboratively, and we can set up runs, manage past runs and documentation, and interpret fluorescent curves remotely and efficiently without the need to install special software," said Dr. Gustav Quade, laboratory medicine and technical development clinical pathologist at Quade Laboratory in Germany.

The Diomni Enterprise software will be available for live demonstrations in Thermo Fisher Scientific’s booth #2118 at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo from July 23-27, 2023 in Anaheim, Calif. To learn more about the Diomni Enterprise Software, please visit thermofisher.com/diomni.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:

Catie Shaw
Phone: 442-303-2104
E-mail: caitlin.campbell@thermofisher.com

Jessika Parry
Phone: 419-266-4016
Email: jparry@greenoughagency.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:

Catie Shaw
Phone: 442-303-2104
E-mail: caitlin.campbell@thermofisher.com

Jessika Parry
Phone: 419-266-4016
Email: jparry@greenoughagency.com

More News From Thermo Fisher

Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma and Applied Testing at ASMS 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today expanded its suite of Thermo Scientific™ Orbitrap™ mass spectrometry platforms, AI-enabled software and integrated workflows at the American Society for Mass Spectrometry (ASMS) Conference. Across research, biopharma and applied testing, scientists face increasingly complex samples, expanding data sets and greater pressure to deliver confident answers faster. Thermo Fisher helps solve that...

Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the Thermo Scientific™ Orbitrap™ Tribrid™ Apex and Thermo Scientific™ Orbitrap™ Excedion™ mass spectrometers will be showcased at the American Society for Mass Spectrometry (ASMS) Conference. As scientific discovery expands into more complex applications—from advanced proteomics and multiomics to biologics and genetic medicines—researchers and drug developers face inc...

Thermo Fisher Scientific Announces Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on July 15, 2026, to shareholders of record as of June 15, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier...
Back to Newsroom